Compare UBC Medical Indonesia Tbk. (LABS) vs Salim Ivomas Pratama Tbk. (SIMP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UBC Medical Indonesia Tbk. vs Salim Ivomas Pratama Tbk. — how do they compare? UBC Medical Indonesia Tbk. trades at Rp148 (market cap 576.7B, 3.48M 24h volume), while Salim Ivomas Pratama Tbk. trades at Rp555 (market cap 8.45T, 6.93M 24h volume). The key difference: Salim Ivomas Pratama Tbk. is far larger — about 14.7× UBC Medical Indonesia Tbk.'s market cap, and Salim Ivomas Pratama Tbk. is more actively traded (6.93M versus 3.48M). Which is the better fit depends on your goals.
| LABS | SIMP | |
|---|---|---|
Market Cap | 576.7B | 8.45T |
Volume | 3.48M | 6.93M |
Lot | 34.82K | 69.29K |
Turnover | 522.79M | 3.81B |
Average Price | 150.13 | 549.27 |
Value | 522.79M | 3.81B |
Indicative Equilibrium Price | 148 | 555 |
Indicative Equilibrium Volume | 350 | 2.29K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UBC Medical Indonesia Tbk.
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →About Salim Ivomas Pratama Tbk.
PT Salim Ivomas Pratama Tbk (the company) was established under its original name of PT Ivomas Pratama base on notarial deed No.65 of Mrs Maria Kidarsa, S.H, dated on 12 Aug, 1992. The Company’s articles of association has been amended several times, most recently by notarial deed No. 46 of Benny Kristianto, S.H., dated Dec 14, 2010, concerning among others, the change in the Company’s name, par value and public offering.
Read more on SIMP →
